PTOISBIBB (08-03)
Approved for use through 07/31/2006 (108-068-1-3031)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to resp Application Number

ORMATION DISCLOSURE ATEMENT BY APPLICANT for submission under 37 CFR 1.99) Examiner Name		
ATEMENT BY APPLICANT for submission under 37 CFR 1.99)		
for submission under 37 CFR 1.99)		
Examiner Name		
Attorney Docket Number PHUS030432US		
<u> </u>		
U.S.PATENTS Remove		
	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
1 5914599 1999-06-22 Sharp all		
2 6252403 2001-06-26 Alsop all		
3 6812696 B1 2004-11-02 Tsukamoto all		
wish to add additional U.S. Patent citation information please click the Add button. Add		
U.S.PATENT APPLICATION PUBLICATIONS Remove		

							_		
	3	6812698	B1	2004-11-02	Tsukamolo		all		
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information	please click th	e Add button.	_	Add	
			U.S.P	ATENT APP	LICATION PU	BLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Pa of cited Doo	atentee or Applicant cument	Relev	s,Columns,Lines wh vant Passages or Re es Appear	
	1								
If you wis	h to a	dd additional U.S. Publ	ished Ap	plication cita	tion information	please click the Ad	d butto	n. Add	
				FOREIGN F	ATENT DOCU	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		d Publication le4 Date	Name of Patente Applicant of cited Document		Pages,Columns,Lir where Relevant Passages or Relevant Figures Appear	Tr
	1								Г

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor Mich		ael A. MORICH
Art Unit		
Examiner Name		
Attornou Docket Numb	or	DUITEDANASSITE

		NON-PATENT LITERATURE DOCUMENTS Remove	
Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.	Тs
	1	CLARE, S., et al.; Compensating for B1 inhomogeneity using active transmit power modulation, 2001; MRM, 19:1349-1352.	
	2	DeDEENE, Y., et al.; Artefacts in multi-echo T2 imaging for high-precision gel dosimetry: II. Analysis of 81-field inhomogenetry, 2000; Phys. Med. Biol.,45:1825-1839.	
	3	DeDEENE, Y., et al.; Validation of MR-Based Polymer Gel Dosmetry as a Precinical Three-Dimensional Verification Tool in Conformal Radiotherapy, 2000; MRM, 43:116-125.	
	4	IBRAHIM, T.S., et al.; Effect of RF coil exotation on field inhomogeneity at ultra high fields: A field optimized TEM resonator; 2001; MRI, 19:1339-1347.	
	5	KINGSLEY, P.B., et al.; Correction of errors caused by imperfect inversion pulses in MR imaging measurement of T1 relexation times; 1998; MRI; 16(9):1049-1055.	
	6	ROSENFELD, D., et al.; Design of selective adiabetic inversion pulses using the adiabetic condition; 1997; J. Mag. Reson; 129:115-124.	
	7	COHEN, M.S., et al.; Rapid and effective correction of RF inhomogeneity for high field magnetic resonance imaging; http://arto.lon.ucia.edu/BMCweb/BMC BIOSMarkCohen/Papers/EQ/; nr Human Bran Mapping.	
	8	Canada National Research Counsil "RF inhomogeneity Compensation" http://bd.nrc-cnrc.gc.ca/fbd_externalitech_commercealizational_rf_ethomogeneity_comp_e.html	

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

	Application Number		
UFORMATION DIGGI COURT	Filing Date		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Michael		ael A. MORICH
Not for submission under 37 CFR 1.99)	Art Unit		
·····,	Examiner Name		
	Attorney Docket Numb	er	PHUS030432US

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.						

See Kind Codes of USPTO Patent Documents at work USPTO.GDV or MPEP 801.64. * Enter office that issued the document, by the two-letter code (WIPO Standard STS.). * The Japanese plant documents, the advisable of the year of the right of the Emperor must precise the sent number of the patent document. Figure 1. The patent of the patent document. Employing bright patent of the patent document work with 90 flowered 51 flowers 2. "Applicat the patent sear a reformation with the patent of the patent document."

Application Number Filing Date Filing Date Filing Date First Number Inventor Michael A. MORICH Art Unit Examiner Name Attorney Cooker Number | PHUS030432US

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the contraction of the

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1 97 and 1 98 to make the appropriate selection(s):

.7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/TML/	Date (YYYY-MM-DD)	2006-04-27
Name/Print	Thomas M. Lundin	Registration Number	48979

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.